e-learning
resources
Madrid 2019
Monday, 30.09.2019
ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dual inhibition of Angiopoietin-2 and VEGF-A with a monoclonal antibody improves pulmonary capillary leakage in murine experimental sepsis
J. Hauschild (Hannover, Germany), I. Temitayo (Hannover, Germany), C. Schrimpf (Hannover, Germany), T. Welte (Hannover, Germany), H. Haller (Hannover, Germany), S. David (Hannover, Germany)
Source:
International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Session:
ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Session type:
Poster Discussion
Number:
2174
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Hauschild (Hannover, Germany), I. Temitayo (Hannover, Germany), C. Schrimpf (Hannover, Germany), T. Welte (Hannover, Germany), H. Haller (Hannover, Germany), S. David (Hannover, Germany). Dual inhibition of Angiopoietin-2 and VEGF-A with a monoclonal antibody improves pulmonary capillary leakage in murine experimental sepsis. 2174
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
Lane-hamilton syndrome and CCF: a fatal association
Related content which might interest you:
Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody
Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020
Year: 2021
Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011
Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model
Source: International Congress 2017 – Experimental PH
Year: 2017
VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Endotoxin reduces VEGF receptor-2 in mouse lung and heart
Source: Eur Respir J 2003; 22: Suppl. 45, 585s
Year: 2003
Hypoxia-induced increase in NO production and eNOS expression by murine pulmonary microvascular endothelial cells
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Vascular endothelial growth factor (VEGF) mRNA isoforms in an animal model of acute lung injury
Source: Annual Congress 2003 - Animal models of lung injury: useful or not?
Year: 2003
Anti-CTGF antibody attenuates silica-induced lung fibrosis in rats
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Implication of aquaporin-1 in the stress response of human pulmonary microvascular endothelial cells
Source: International Congress 2019 – Biomarkers, laboratory findings and pre-clinical data in acute respiratory failure
Year: 2019
VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Vascular endothelial growth factor (VEGF) and CD31 expression in experimental prosthetic tracheal replacement
Source: Annual Congress 2009 - Current challenges in thoracic surgery
Year: 2009
Intravenous anti-vascular endothelial growth factor antibody decreases pleural fluid volume in experimental pleurodesis induced by silver nitrate
Source: Annual Congress 2007 - Pleural diseases
Year: 2007
Identification of target antigens of anti-fibroblast antibodies in pulmonary arterial hypertension
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung
Source: Eur Respir J 2006; 28: Suppl. 50, 822s
Year: 2006
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis
Source: Eur Respir J 2016; 47:1481-1491
Year: 2016
Iloprost protects against lung endothelial barrier dysfunction and vascular leak via Rap1
Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury
Year: 2009
Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients
Source: Eur Respir J 2003; 22: Suppl. 45, 173s
Year: 2003
Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept